Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma

Christina Pfannenberg; Philip Aschoff; Sandra Schanz; Susanne M. Eschmann; Christian Plathow; Thomas K. Eigentler; Claus Garbe; Klaus Brechtel; Reinhard Vonthein; Roland Bares; Claus D. Claussen; Heinz P. Schlemmer

doi:10.1016/j.ejca.2006.11.014

Prospective comparison of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma

Christina Pfannenberg^*, Philip Aschoff, Sandra Schanz, Susanne M. Eschmann, Christian Plathow, Thomas K. Eigentler, Claus Garbe, Klaus Brechtel, Reinhard Vonthein, Roland Bares, Claus D. Claussen, Heinz P. Schlemmer

^*Corresponding author for this work

Institute of Medical Biometry and Statistics

University of Tubingen

181 Citations (Scopus)

Abstract

The aim of our study was to compare the overall and site-based accuracy and impact on patient management of positron emission tomography/computed tomography (PET/CT) and whole-body (wb) magnetic resonance imaging (MRI) in staging of advanced melanoma. In a prospective blinded study, 64 patients with American Joint Committee on Cancer (AJCC) stage III/IV melanoma underwent ¹⁸F-fluorodeoxyglucose PET/CT and wbMRI. In total 420 lesions were evaluated. The overall accuracy of PET/CT was 86.7% compared to 78.8% for wbMRI (P = 0.0007). PET/CT was significantly more accurate in N-staging and detecting of skin and subcutaneous metastases, whereas wbMRI was more sensitive in detecting liver, bone and brain metastases. WbMRI was less sensitive but more specific than PET/CT in classifying pulmonary lesions. In 41 patients (64%) whole-body imaging caused changes of treatment. Whole-body staging of patients with advanced melanoma is most accurate by combining wbPET/CT and organ-specific wbMRI including a brain, liver and bone marrow protocol.

Original language	English
Journal	European Journal of Cancer
Volume	43
Issue number	3
Pages (from-to)	557-564
Number of pages	8
ISSN	0959-8049
DOIs	https://doi.org/10.1016/j.ejca.2006.11.014
Publication status	Published - 02.2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ejca.2006.11.014

Cite this

Pfannenberg, C., Aschoff, P., Schanz, S., Eschmann, S. M., Plathow, C., Eigentler, T. K., Garbe, C., Brechtel, K., Vonthein, R., Bares, R., Claussen, C. D., & Schlemmer, H. P. (2007). Prospective comparison of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. European Journal of Cancer, 43(3), 557-564. https://doi.org/10.1016/j.ejca.2006.11.014

@article{750f7cd3b46c4e1a857bb54e1071c974,

title = "Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma",

abstract = "The aim of our study was to compare the overall and site-based accuracy and impact on patient management of positron emission tomography/computed tomography (PET/CT) and whole-body (wb) magnetic resonance imaging (MRI) in staging of advanced melanoma. In a prospective blinded study, 64 patients with American Joint Committee on Cancer (AJCC) stage III/IV melanoma underwent 18F-fluorodeoxyglucose PET/CT and wbMRI. In total 420 lesions were evaluated. The overall accuracy of PET/CT was 86.7\% compared to 78.8\% for wbMRI (P = 0.0007). PET/CT was significantly more accurate in N-staging and detecting of skin and subcutaneous metastases, whereas wbMRI was more sensitive in detecting liver, bone and brain metastases. WbMRI was less sensitive but more specific than PET/CT in classifying pulmonary lesions. In 41 patients (64\%) whole-body imaging caused changes of treatment. Whole-body staging of patients with advanced melanoma is most accurate by combining wbPET/CT and organ-specific wbMRI including a brain, liver and bone marrow protocol.",

author = "Christina Pfannenberg and Philip Aschoff and Sandra Schanz and Eschmann, \{Susanne M.\} and Christian Plathow and Eigentler, \{Thomas K.\} and Claus Garbe and Klaus Brechtel and Reinhard Vonthein and Roland Bares and Claussen, \{Claus D.\} and Schlemmer, \{Heinz P.\}",

year = "2007",

month = feb,

doi = "10.1016/j.ejca.2006.11.014",

language = "English",

volume = "43",

pages = "557--564",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "3",

}

Pfannenberg, C, Aschoff, P, Schanz, S, Eschmann, SM, Plathow, C, Eigentler, TK, Garbe, C, Brechtel, K, Vonthein, R, Bares, R, Claussen, CD & Schlemmer, HP 2007, 'Prospective comparison of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma', European Journal of Cancer, vol. 43, no. 3, pp. 557-564. https://doi.org/10.1016/j.ejca.2006.11.014

Prospective comparison of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. / Pfannenberg, Christina; Aschoff, Philip; Schanz, Sandra et al.
In: European Journal of Cancer, Vol. 43, No. 3, 02.2007, p. 557-564.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma

AU - Pfannenberg, Christina

AU - Aschoff, Philip

AU - Schanz, Sandra

AU - Eschmann, Susanne M.

AU - Plathow, Christian

AU - Eigentler, Thomas K.

AU - Garbe, Claus

AU - Brechtel, Klaus

AU - Vonthein, Reinhard

AU - Bares, Roland

AU - Claussen, Claus D.

AU - Schlemmer, Heinz P.

PY - 2007/2

Y1 - 2007/2

N2 - The aim of our study was to compare the overall and site-based accuracy and impact on patient management of positron emission tomography/computed tomography (PET/CT) and whole-body (wb) magnetic resonance imaging (MRI) in staging of advanced melanoma. In a prospective blinded study, 64 patients with American Joint Committee on Cancer (AJCC) stage III/IV melanoma underwent 18F-fluorodeoxyglucose PET/CT and wbMRI. In total 420 lesions were evaluated. The overall accuracy of PET/CT was 86.7% compared to 78.8% for wbMRI (P = 0.0007). PET/CT was significantly more accurate in N-staging and detecting of skin and subcutaneous metastases, whereas wbMRI was more sensitive in detecting liver, bone and brain metastases. WbMRI was less sensitive but more specific than PET/CT in classifying pulmonary lesions. In 41 patients (64%) whole-body imaging caused changes of treatment. Whole-body staging of patients with advanced melanoma is most accurate by combining wbPET/CT and organ-specific wbMRI including a brain, liver and bone marrow protocol.

AB - The aim of our study was to compare the overall and site-based accuracy and impact on patient management of positron emission tomography/computed tomography (PET/CT) and whole-body (wb) magnetic resonance imaging (MRI) in staging of advanced melanoma. In a prospective blinded study, 64 patients with American Joint Committee on Cancer (AJCC) stage III/IV melanoma underwent 18F-fluorodeoxyglucose PET/CT and wbMRI. In total 420 lesions were evaluated. The overall accuracy of PET/CT was 86.7% compared to 78.8% for wbMRI (P = 0.0007). PET/CT was significantly more accurate in N-staging and detecting of skin and subcutaneous metastases, whereas wbMRI was more sensitive in detecting liver, bone and brain metastases. WbMRI was less sensitive but more specific than PET/CT in classifying pulmonary lesions. In 41 patients (64%) whole-body imaging caused changes of treatment. Whole-body staging of patients with advanced melanoma is most accurate by combining wbPET/CT and organ-specific wbMRI including a brain, liver and bone marrow protocol.

UR - https://www.scopus.com/pages/publications/33846587851

U2 - 10.1016/j.ejca.2006.11.014

DO - 10.1016/j.ejca.2006.11.014

M3 - Journal articles

C2 - 17224266

AN - SCOPUS:33846587851

SN - 0959-8049

VL - 43

SP - 557

EP - 564

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 3

ER -

Prospective comparison of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this